The recent clinical success of MEK inhibition with selumetinib in NF1 plexiform neurofibromas and recent preclinical MPNST treatment studies highlight the therapeutic potential of targeting MEK in NF1-related MPNSTs [28,29,30]. This evidence concerns the gene MAP2K7 and neurofibromatosis type 1.